The appropriate staging and treatment of patients with stage I and II non-small-cell lung cancer (NSCLC) are important in that the potential for a lost curative opportunity in this population is greater than for those presenting with advanced NSCLC.
Methods
Treatment options – surgery, radiation therapy, and chemotherapy – for stage I and II NSCLC are reviewed, and the impact of newer staging modalities on patient survival is discussed, including altering both the lead-time and clinicopathologic stage biases that exist in the diagnosis and treatment of NSCLC. Some predictions are also made regarding how that standard may change for clinicians in the near future, and methods for further improvements in posttreatment survival in this group are discussed.
Results
Whenever possible, patients with early-stage NSCLC should be treated with surgical resection. Patients for whom resection is not an option may benefit from radiation as definitive therapy. Positive results with neoadjuvant chemotherapy have led to an ongoing randomized trial (Intergroup S9900) to compare surgery alone to neoadjuvant chemotherapy plus surgery.
Conclusions
Staging bias may affect the overall low survival of early-stage NSCLC. However, true stage-specific survival may improve with newer imaging modalities. Future advances, including closed transthoracic radiation, thermal ablative therapy techniques, and gene therapy, may supplant the need to surgically resect these tumors to achieve local control.
References
1.
RiesL.A., WingoP.A., MillerD.S.. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer.Cancer.2000; 88: 2398–2424.
NarukeT., GoyaT., TsuchiyaR.. Prognosis and survival in resected lung carcinoma based on the new international staging system.J Thorac Cardiovasc Surg.1988; 96: 440–447.
4.
MountainC.F.. Revisions in the international system for staging lung cancer.Chest.1997; 111: 1710–1717.
5.
PietermanR.M., van PuttenJ.W., MeuzelaarJ.J.. Preoperative staging of non-small-cell lung cancer with positron-emission tomography.N Engl J Med.2000; 343: 254–261.
6.
HillersT.K., SauveM.D., GuyattG.H.. Analysis of published studies on the detection of extrathoracic metastases in patients presumed to have operable non-small cell lung cancer.Thorax.1994; 49: 14–19.
7.
TarverR.D., RichmondB.D., KlatteE.C.. Cerebral metastases from lung carcinoma: neurological and CT correlation. Work in progress.Radiology.1984; 153: 689–692.
8.
SalbeckR., GrauH.C., ArtmannH.. Cerebral tumor staging in patients with bronchial carcinoma by computed tomography.Cancer.1990; 66: 2007–2011.
9.
YokoiK., KamiyaN., MatsugumaH.. Detection of brain metastasis in potentially operable non-small cell lung cancer: a comparison of CT and MRI.Chest.1999; 115: 714–719.
10.
LondonA.J.. The ambiguity and the exigency: clarifying “standard of care” arguments in international research.J Med Philos.2000; 25: 379–397.
11.
HoffmannT.H., RansdellH.T.. Comparison of lobectomy and wedge resection for carcinoma of the lung.J Thorac Cardiovasc Surg.1980; 79: 211–217.
12.
ErrettL.E., WilsonJ., ChiuR.C.. Wedge resection as an alternative procedure for peripheral bronchogenic carcinoma in poor-risk patients.J Thorac Cardiovasc Surg.1985; 90: 656–661.
13.
McCormackP.M., MartiniN.. Primary lung carcinoma: results with conservative resection in treatment.N Y State J Med.1980; 80: 612–616.
14.
MartiniN., BainsM.S., BurtM.E.. Incidence of local recurrence and second primary tumors in resected stage I lung cancer.J Thorac Cardiovasc Surg.1995; 109: 120–129.
15.
GinsbergR.J., RubinsteinL.V.. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group.Ann Thorac Surg.1995; 60: 615–622.
16.
LewisR.J., CaccavaleR.J., SislerG.E.. One hundred video-assisted thoracic surgical simultaneously stapled lobectomies without rib spreading.Ann Thorac Surg.1997; 63: 1415–1421.
17.
NakataM., SaekiH., YokoyamaN.. Pulmonary function after lobectomy: video-assisted thoracic surgery versus thoracotomy.Ann Thorac Surg.2000; 70: 938–941.
18.
IshidaT., YanoT., MaedaK.. et al. Strategy for lymphadenectomy in lung cancer three centimeters or less in diameter.Ann Thorac Surg.1990; 50: 708–713.
19.
SugiK., NawataK., FujitaN.. Systematic lymph node dissection for clinically diagnosed peripheral non-small-cell lung cancer less than 2 cm in diameter.World J Surg.1998; 22: 290–294.
20.
TakizawaT., TerashimaM., KoikeT.. Lymph node metastasis in small peripheral adenocarcinoma of the lung.J Thorac Cardiovasc Surg.1998; 116: 276–280.
21.
GrahamP.H., GebskiV.J., LanglandsA.O.. Radical radiotherapy for early nonsmall cell lung cancer.Intl J Radiat Oncol Biol Phys.1995; 31: 261–266.
22.
KellerS.M., AdakS., WagnerH.. Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer. Eastern Cooperative Oncology Group.Ann Thorac Surg.2000; 70: 358–365.
LittleA.G., DeHoyosA., KirganD.M.. Intraoperative lymphatic mapping for non-small cell lung cancer: the sentinel node technique.J Thorac Cardiovasc Surg.1999; 117: 220–234.
25.
MoritaK., FuwaN., SuzukiY.. Radical radiotherapy for medically inoperable non-small cell lung cancer in clinical stage I: a retrospective analysis of 149 patients.Radiother Oncol.1997; 42: 31–36.
26.
KupelianP.A., KomakiR., AllenP.. Prognostic factors in the treatment of node-negative nonsmall lung carcinoma with radiotherapy alone.Int J Radiat Oncol Biol Phys.1996; 36: 607–613.
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised trials.Non-small Cell Lung Cancer Collaborative Group.BMJ.1995; 311: 899–909.
29.
RothJ.A., AtkinsonE.N., FossellaF.. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.Lung Cancer.1998; 21: 1–6.
30.
RosellR., Gomez-CodinaJ., CampsC.. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.N Engl J Med.1994; 330: 153–158.
31.
SugarbakerD.J., HerndonJ., KohmanL.J.. Results of cancer and leukemia group B protocol 8935: a multiinstitutional phase II tri-modality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group.J Thorac Cardiovasc Surg.1995; 109: 473–483.
32.
AlbainK.S., RuschV.W., CrowleyJ.J.. Concurrent cis-platin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.J Clin Oncol.1995; 13: 1880–1892.
33.
IchnoseY., TsuchiyaR., KatoH.. Randomized trial of chemotherapy followed by surgery versus surgery for stage IIIA N2 non-small cell lung cancer: the Japan Clinical Oncology Group 9209.Lung Cancer.2000; 29(suppl 2): 173.
34.
WagnerJJr, LadT., PiantadoseS.. Randomized phase 2 evaluation of preoperative radiation therapy and preoperative chemotherapy with mitomycin, vinblastine, and cisplatin in patients with technically unresectable stage IIIA and IIIB non-small cell cancer of the lung: LCSG 881.Chest.1994; 106(suppl 6): 348S–354S.
35.
EliasA.D., HerndonJ., KumarP.. A phase III comparison of “best local-regional therapy”with or without chemotherapy (CT) for stage IIIA T1-3N2 non-small cell lung cancer (NSCLC): preliminary results.Proc Annu Meet Am Soc Clin Oncol.1997; 16: A1611.
36.
SiegenthalerM.P., PistersK.M., MerrimanK.W.. Preoperative chemotherapy for lung cancer does not increase surgical morbidity.Ann Thorac Surg.2001; 71: 1105–1111.
37.
PistersK.M., GinsbergR.J., GirouxD.J.. Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. Bimodality Lung Oncology Team.J Thorac Cardiovasc Surg.2000; 119: 429–439.
38.
BurtonE.C., TroxclairD.A., NewmanWPIII. Autopsy diagnoses of malignant neoplasms: how often are clinical diagnoses incorrect?JAMA.1998; 280: 1245–1248.
39.
BuryT., DowlatiA., PaulusP.. Whole-body 18FDG positron emission tomography in the staging of non- small cell lung cancer.Eur Respir J.1997; 10: 2529–2534.
40.
WederW., SchmidR.A., BruchhausH.. Detection of extrathoracic metastases by positron emission tomography in lung cancer.Ann Thorac Surg.1998; 66: 886–892.
41.
GuptaN.C., GraeberG.M., RogersJSII. Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer.Ann Surg.1999; 229: 286–291.
42.
CoteR.J., HawesD., ChaiwunB.. Detection of occult metastases in lung carcinomas: progress and implications for lung cancer staging.J Surg Oncol.1998; 69: 265–274.
43.
OhgamiA., MitsudomiT., SugioK.. Micrometastatic tumor cells in the bone marrow of patients with non-small cell lung cancer.Ann Thorac Surg.1997; 64: 363–367.
44.
PantelK., IzbickiJ., PasslickB.. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases.Lancet.1996; 347: 649–653.
45.
PasslickB., KubuschokB., IzbickiJ.R.. Isolated tumor cells in bone marrow predict reduced survival in node-negative non-small cell lung cancer.Ann Thorac Surg.1999; 68: 2053–2058.
46.
MaruyamaR., SugioK., MitsudomiT.. Relationship between early recurrence and micrometastases in the lymph nodes of patients with stage I non-small-cell lung cancer.J Thorac Cardiovasc Surg.1997; 114: 535–543.
47.
HenschkeC.I., McCauleyD.I., YankelevitzD.F.. Early Lung Cancer Action Project: overall design and findings from baseline screening.Lancet.1999; 354: 99–105.
48.
PatzEFJr, RossiS., HarpoleDHJr. Correlation of tumor size and survival in patients with stage IA non- small cell lung cancer.Chest.2000; 117: 1568–1571.
49.
YoshidaJ., NagaiK., YokoseT.. Primary peripheral lung carcinoma smaller than 1 cm in diameter.Chest.1998; 114: 710–712.
TurszT., CesneA.L., BaldeyrouP.. Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients.J Natl Cancer Inst.1996; 88: 1857–1863.
52.
RothJ.A., SwisherS.G., MerrittJ.A.. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement.Semin Oncol.1998; 25: 33–37.
